Table S1.
Analysis of percentage change from baseline at study endpoint (ie, last post-week 6 measurement) in LDL-C, non-HDL-C, and apoB in the pooled treatment groups for the overall population and patient subgroups defined by baseline TG <2.26 and ≥2.26 mmol/L
| N | LS mean percentage change from baseline at study endpoint (CI) | |
|---|---|---|
| LDL-C | ||
| ERN/LRPT | 160 | −15.2 (−17.9 to −12.4) |
| TG <2.26 mmol/L | 124 | −17.6 (−20.6 to −14.6) |
| TG ≥2.26 mmol/L | 36 | −6.9 (−13.0 to 0.8) |
| Pooled SIMVA | 564 | −35.8 (−37.2 to −34.3) |
| TG <2.26 mmol/L | 447 | −36.9 (−38.5 to −35.3) |
| TG ≥2.26 mmol/L | 117 | −31.3 (−35.0 to −27.6) |
| Pooled ERN/LRPT + SIMVA | 519 | −47.2 (−49.2 to −45.1) |
| TG <2.26 mmol/L | 419 | −48.7 (−50.9 to −46.5) |
| TG ≥2.26 mmol/L | 100 | −40.9 (−46.0 to −35.8) |
| Non-HDL-C | ||
| ERN/LRPT | 160 | −16.4 (−18.9 to −13.9) |
| TG <2.26 mmol/L | 124 | −17.6 (−20.4 to −14.7) |
| TG ≥2.26 mmol/L | 36 | −12.5 (−17.7 to −7.2) |
| Pooled SIMVA | 564 | −32.0 (−33.3 to −30.6) |
| TG <2.26 mmol/L | 447 | −32.9 (−34.3 to −31.4) |
| TG ≥2.26 mmol/L | 117 | −28.6 (−31.6 to −25.5) |
| Pooled ERN/LRPT + SIMVA | 519 | −44.8 (−46.7 to −42.9) |
| TG <2.26 mmol/L | 419 | −45.8 (−47.9 to −43.7) |
| TG ≥2.26 mmol/L | 100 | −40.8 (−45.1 to −36.5) |
| ApoB | ||
| ERN/LRPT | 155 | −15.1 (−17.5 to −12.6) |
| TG <2.26 mmol/L | 121 | −15.5 (−18.3 to −12.7) |
| TG ≥2.26 mmol/L | 34 | −13.3 (−18.7 to −8.0) |
| Pooled SIMVA | 560 | −27.3 (−28.6 to −26.0) |
| TG <2.26 mmol/L | 444 | −28.1 (−29.4 to −26.7) |
| TG ≥2.26 mmol/L | 116 | −24.4 (−27.9 to −20.9) |
| Pooled ERN/LRPT + SIMVA | 516 | −39.8 (−41.7 to −37.9) |
| TG <2.26 mmol/L | 417 | −40.1 (−42.3 to −37.9) |
| TG ≥2.26 mmol/L | 99 | −38.6 (−42.6 to −34.6) |
Abbreviations: apoB, apolipoprotein B; CI, confidence interval; ERN, extended-release niacin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LRPT, laropiprant; LS, least squares; SIMVA, simvastatin; TG, triglyceride.